Lat­est J&J-part­nered Leg­end Biotech da­ta spot­light con­tin­ued high re­sponse rate but 10 pa­tient deaths

Leg­end Biotech has has a good three years ever since the then-lit­tle known biotech un­veiled a round of BC­MA CAR-T da­ta at AS­CO. It helped net them a part­ner­ship with J&J and, more re­cent­ly, one of biotech his­to­ry’s biggest IPOs.

Now, the Nan­jing-based biotech un­veiled their largest set of da­ta for the ther­a­py, show­ing in­ter­im re­sults from a piv­otal US study con­duct­ed with J&J. The da­ta af­firmed the drug’s now well-doc­u­ment­ed ef­fi­ca­cy, with a 94% re­sponse rate and a 55% com­plete re­sponse rate, but it al­so re­vealed that, out of 97 pa­tients in the study, 10 died.

Eight of the deaths were from ad­verse events — whether re­lat­ed or un­re­lat­ed — and two were from dis­ease pro­gres­sion. No­tably, though, on­ly one death was from cy­tokine re­lease syn­drome, the in­flam­ma­to­ry con­di­tion that has dogged CAR-T since the first ex­per­i­men­tal ther­a­pies were put in­to hu­mans.

Leg­end dis­closed the CRS death, along with two oth­ers, in their S-1 this spring.

The com­pa­ny al­so not­ed a 20.6% rate of neu­ro­tox­i­c­i­ty, an­oth­er com­mon dan­ger­ous CAR-T side ef­fect. Af­ter the last cut of da­ta in 29 pa­tients in De­cem­ber, they had said “neu­ro­tox­i­c­i­ty was in­fre­quent­ly ob­served.”

Of course, se­vere side ef­fects have not al­ways held up CAR-T treat­ments in the past, par­tic­u­lar­ly when they al­so brought com­pelling ef­fi­ca­cy da­ta, and the J&J in­ves­ti­ga­tors said the da­ta were “con­sis­tent” with pri­or stud­ies. No­var­tis, for in­stance, saw 3 deaths in its piv­otal study for Kym­ri­ah and more than half of its pa­tients ex­pe­ri­ence neu­ro­log­i­cal symp­toms.

Safe­ty splits could be­come par­tic­u­lar­ly rel­e­vant, though, as J&J seeks to go head-to-head with the ri­val mul­ti­ple myelo­ma CAR-T treat­ment from blue­bird and Bris­tol My­ers Squibb, which is al­ready sit­ting be­fore the FDA.

In their most re­cent phase II da­ta, blue­bird sim­i­lar­ly saw one CRS-re­lat­ed death out of 140 pa­tients, but didn’t dis­close oth­er deaths in the tri­al. They re­port­ed that 3.1% of pa­tients had grade 3 or high­er neu­ro­tox­i­c­i­ties.

That da­ta set al­so showed re­duced ef­fi­ca­cy com­pared to what Leg­end showed in to­day’s cut, con­tin­u­ing a trend since AS­CO 2017. (Blue­bird main­tained at the time that Leg­end chose eas­i­er pa­tients). They saw an 81.5% re­sponse rate in the high­est per­form­ing dose group, with 35.2% see­ing some form of com­plete re­sponse.

J&J wasn’t yet able to col­lect du­ra­tion of re­sponse da­ta, but they showed that one pa­tient has re­spond­ed for around 20 months. Of pa­tients who were fol­lowed for 6 months, 87.4% had not seen their can­cers progress at that time and 93.8% were still alive.

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may remember that at the beginning of this year, Endpoints News set a goal to go broader and deeper. We are still working towards that, and are excited to share that Beth Snyder Bulik will be joining us on Monday to cover all things pharma marketing. You can sign up for her weekly Endpoints MarketingRx newsletter in your reader profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis de­vel­op­ment chief John Tsai: 'We go deep in the new plat­form­s'

During our recent European Biopharma Summit, I talked with Novartis development chief John Tsai about his experiences over the 3-plus years he’s been at the pharma giant. You can read the transcript below or listen to the exchange in the link above.

John Carroll: I followed your career for quite some time. You’ve had more than 20 years in big pharma R&D and you’ve obviously seen quite a lot. I really was curious about what it was like for you three and a half years ago when you took over as R&D chief at Novartis. Obviously a big move, a lot of changes. You went to work for the former R&D chief of Novartis, Vas Narasimhan, who had his own track record there. So what was the biggest adjustment when you went into this position?

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca

As­traZeneca on­col­o­gy R&D chief Su­san Gal­braith: 'Y­ou're go­ing to need or­thog­o­nal com­bi­na­tion­s'

 

Earlier in the week we broadcast our 4th annual European Biopharma Summit with a great lineup of top execs. One of the one-on-one conversations I set up was with Susan Galbraith, the oncology research chief at AstraZeneca. In a wide-ranging discussion, Galbraith reviewed the cancer drug pipeline and key trends influencing development work at the pharma giant. You can watch the video, above, or stick with the script below. — JC

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Amit Etkin, Alto Neuroscience CEO (Alto via Vimeo)

A star Stan­ford pro­fes­sor leaves his lab for a start­up out to re­make psy­chi­a­try

About five years ago, Amit Etkin had a breakthrough.

The Stanford neurologist, a soft-spoken demi-prodigy who became a professor while still a resident, had been obsessed for a decade with how to better define psychiatric disorders. Drugs for depression or bipolar disorder didn’t work for many patients with the conditions, and he suspected the reason was how traditional diagnoses didn’t actually get at the heart of what was going on in a patient’s brain.

Roche's Tecen­triq cross­es the fin­ish line first in ad­ju­vant lung can­cer, po­ten­tial­ly kick­ing off gold rush

While falling behind the biggest PD-(L)1 drugs in terms of sales, Roche has looked to carve out a space for its Tecentriq with a growing expertise in lung cancer. The drug will now take an early lead in the sought-after adjuvant setting — but competitors are on the way.

The FDA on Friday approved Tecentriq as an adjuvant therapy for patients with Stage II-IIIA non small cell lung cancer with PD-(L)1 scores greater than or equal to 1, making it the first drug of its kind approved in an early setting that covers around 40% of all NSCLC patients.

Susan Galbraith speaking at Endpoints News' virtual EUBIO21 summit

Imfinzi/treme­li­mum­ab com­bo scores As­traZeneca an­oth­er OS win — this time in liv­er can­cer

Is the tide turning on AstraZeneca’s battered PD-L1/CTLA4 combo?

A single priming dose of the experimental tremelimumab, followed by Imfinzi every four weeks, beat Nexavar (sorafenib) in helping a group of liver cancer patients live longer in a Phase III study, the company reported, meeting the primary endpoint.

Specifically, the two drugs extended overall survival for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.

FDA ad­comm votes unan­i­mous­ly in sup­port of a J&J Covid-19 boost­er two months af­ter one-dose shot

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Friday voted 19-0 in favor of authorizing a second shot of J&J’s Covid-19 vaccine to follow at least two months after the initial dose.

Regulators don’t have to follow VRBPAC’s recommendation, but they almost always do. Considering that the CDC’s advisory committee has already been set to review the expanded EUA, VRBPAC’s recommendation is likely to be adopted.

FDA+ roundup: Marks on Wood­cock­'s tenure as act­ing com­mis­sion­er; FDA lead­ers of­fer per­spec­tive on bar­ri­ers to di­ver­si­ty in re­search

CBER director Peter Marks praised Janet Woodcock’s work as acting FDA commissioner, and while noting that Biden needs to nominate someone to fill the role permanently by Nov. 16, he said he has “no idea” when that actually might occur.

“Dr. Woodcock has been at the agency for over three decades and she, during that time, has proven herself to be a remarkably capable manager,” Marks said at the Alliance for Regenerative Medicine’s meeting Tuesday. “And she’s been managing as if she’s commissioner, unlike some previous acting [commissioners] who are afraid to actually do things. She doesn’t appear to be afraid to do things. I have not felt any different now from when we had a commissioner in place,” he added.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.